Follow us:

Exklusiver
Vertriebspartner

Medizinisches Fachpersonal

Fallbeispiele

Praxisnahe Evidenz für fundierte Therapieentscheidungen
euSkin verfolgt einen evidenzbasierten Ansatz bei der Entwicklung seiner RSL-Produkte. Neben wissenschaftlichen Untersuchungen gewinnen Real-World Data und daraus abgeleitete Real-World Evidence zunehmend an Bedeutung, da sie die Wirksamkeit und Sicherheit von Produkten unter Alltagsbedingungen dokumentieren. Unsere Case Studies zeigen ausgewählte klinische Anwendungsfälle und veranschaulichen die Behandlungsergebnisse in der medizinischen Praxis. Sie stellen eine wertvolle Ergänzung zur wissenschaftlichen Evidenz dar und unterstützen den Wissenstransfer in den klinischen Alltag.

Sehr gerne sende wir Ihnen per Mail eine Sammlung von Case Studies zur Anwendung der euSkin Produkte zu.

Test-Paket

Praxisnahe Produkterfahrung für den klinischen Einsatz
Der erfolgreiche Einsatz moderner Wundversorgungsprodukte setzt neben wissenschaftlicher Evidenz auch praktische Anwendungserfahrung voraus. Mit dem euSkin® Test-Paket erhalten medizinische Fachkräfte ausgewählte Produktmuster sowie ergänzende Informationsmaterialien für Patientinnen und Patienten und Pflegepersonal. Das Paket ermöglicht eine strukturierte Erprobung der RSL-Produkte im klinischen Alltag und unterstützt eine fundierte Bewertung ihrer Anwendungsmöglichkeiten in der individuellen Versorgung.

Bestellen Sie einfach über das unten stehende Kontaktformular ein Test-Paket und wir freuen uns, Ihnen dieses unverzüglich zuzusenden.

Publikationen

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.

Kontakt

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.

Wünsche einen Anruf
Wünsche Besuch
Wünsche Kontakt per Mail

Mitigating radiation dermatitis in breast cancer patients through early skin preparation:

A clinical trial of an atelocollagen complex-based intervention - key summary

 

 

Despoina Kokkinidou 1 , Constantina Cloconi 2 , Antria Savva 2 , Christina Georgiou 2 , Maria Kyprianidou 3 , Eleftheria Sidira 1 , Anna Christofini 1 , Konstantinos Ferentinos 2 , Angelos Kassianos 3 , Constantinos Zamboglou 2 , Marianna Prokopi-Demetriades 1

1 RSL Revolutionary Labs Ltd, Limassol, Cyprus,
2 German Medical Institute, Limassol, Cyprus,
3 Cyprus University of Technology, Limassol, Cyprus

 

 

METHODS

A randomized, double-blind, controlled clinical trial was conducted at the German Medical Institute in Cyprus, involving 80 breast cancer patients undergoing radiotherapy. Participants were randomized into two groups: an intervention group using the atelocollagen-based cream (ATC; 0.1% triple atelocollagen complex-based cream) and a control group receiving standard of care (SOC; 2% panthenol-based cream).

The product was administered beginning one day prior to the initiation of radiation therapy and continued throughout the treatment period, and radiation dermatitis severity was evaluated weekly during the radiotherapy session and at two post-treatment follow-ups (1-week and 1-month post-radiation treatment) using CTCAE guidelines assessment and photography documentation.

Over 90 % full recovery 1 month post-therapy with ATC cream vs < 50 % with SOC

**** p < 0.0001

At one-month post-therapy, over 93% of patients in the intervention group achieved full recovery, compared to less than 50% in the control group. Grade II radiodermatitis was effectively prevented in the intervention group and reductions in skin or nipple-areolar hyperpigmentation were observed, with the intervention group reporting less severe side effects at all timepoints.

Higher psychosocial well-being and comfort scores only in the ATC group

Significant improvement in psychosocial health and symptom management.

Psychosocial Health, where results indicate an increase in overall psychosocial well-being only in the ATC group, while the SOC group showed a decline.

SUMMARY OF RESULTS

At 1-month post-treatment

  • Over 90% full recovery 1-month post-therapy with the ATC cream versus less than 50% with SOC.
  • Less severe side effects with the ATC cream at all time points.
  • The protective effect of ATC became more evident over time, with a greater proportion of patients exhibiting lower radiodermatitis grades.
  • A substantial proportion of the SOC (50%) continued to exhibit Grade I radiodermatitis.
  • The incidence of Grade II radiodermatitis was minimal in the ATC group, while it persisted in the SOC.
  • The differences between the groups remained highly statistically significant.

CONCLUSION

Early application of the atelocollagen complex-based dermaceutical cream significantly reduced radiation dermatitis severity and enhanced recovery compared to standard care.
These findings highlight its potential as an effective protective intervention. Further validation through larger-scale clinical trials is warranted to confirm its efficacy and long-term benefits.

2025 Targeted Malignent Wound Healing with miRNA-Enhanced MSC-derived EVs in a sustained-released Atelocollagen Hydrogel

ISEV 2025
Vienna, Austria